Mark Snyder

Mark Snyder

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate SecretaryatHalozyme Therapeutics· In proxies 2022–2025

Pay in FY2025-16% from the year before · Halozyme Therapeutics stock +40.8% the same year

Mark Snyder was paid $4.5M in FY2025 (Dec), down 16%. Halozyme Therapeutics stock rose 40.8% that year.

Pay$100 in the stock at the end of FY21 → $167
Pay is from the Summary Compensation Table of each Halozyme Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Halozyme TherapeuticsPublic company · 4 yr
    • Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary2022 – Present · 4 yrStock in role +222%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?